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Significance for Public Health 
Peripheral artery disease (PAD) is a benign multifactorial condition associated with high morbidity and 
mortality; the femoral-popliteal axis is one of the most critical vascular district due to its complex 
biodynamic. Although balloon angioplasty represents the first line treatment, it is not uncommon the 
use of stents in order to preserve patency vessel. Among different stents available, however, Supera 
peripheral stent (Abbott Vascular, Santa Rosa, CA, USA) has the ability to fit better to the femoro-
popliteal compartment which is subject to biomechanical stress. The aim of this paper is to 
retrospectively analyze a multicentric experience with the use of a specific device (Supera peripheral 
stent) for treatment of PAD in femoral-popliteal disease, comparing results with Literature. Through 
this paper, every interventional radiologist interested in PAD endovascular treatment could have an 




Background: Even though many types of stents have been tested in superficial femoral artery (SFA) 
and popliteal artery (PA), the vast majority of these devices have provided an unsatisfactory outcome, 
probably due their unsuitable anatomical and physiological characteristics. The Supera peripheral stent 
(Abbott Vascular, Santa Rosa, CA, USA) is a braided interwoven nitinol device specifically designed 
for treating atherosclerotic lesions of the femoro-popliteal segment. The aim of this multicenter 
retrospective study was to describe the effectiveness of Supera stents in the management of femoral-
popliteal atherosclerotic lesions and to critically analyze our findings in the context of current and past 
literature.  
Design and Methods: In this study we enrolled only patients who satisfied the inclusion criteria: 1) 
patients affected by chronic obstructive arterial disease (COAD) grade II, as per Rutherford 
classification; 2) patients treated with endovascular revascularization and Supera stent implantation in 
the femoro-popliteal axis. We retrospectively analyzed the Doppler Ultra-sound (US) follow-up at 12-
24 and 36 month in order to detect the vascular occlusions. The primary patency, primary patency 
assisted and TLR were described statistically analyzed by survival analysis and the demographic data, 
clinical data, device safety following stenting were described as frequency and mean value. 
Results ì: 105 endovascular procedures on 99 patients for femoro-popliteal stenting with Supera were 
performed in four Italian hospitals. The median follow-up was 39 months (range 6-72), with primary 
patency rate of 83.1%, 74.3% and 69.5% at 12, 24 and 36 months after the procedure. The primary 
patency assisted was 89.9%, 76.8% and 73.4% in the same period, while the freedom from TLR values 
were 92.7%, 91.5% and 89.5% at 12, 24 and 36 months after the procedure, respectively. The mortality 
rate recorded at 12 months from the Supera implantation was 2.8% (3 out of 99 patients enrolled).  
Conclusions: Our data were in agree with the current literature, showing the non-inferiority Supera 
stent in relation to the other stent available. Supera stent showed an excellent safety, effectiveness 
profile and high durability for the treatment of PAD patients with femoro-popliteal artery disease. 
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Introduction 
Peripheral artery disease (PAD) is a multifactorial condition associated with high morbidity and 
mortality, with an increasing incidence in Western countries (1) due to the widespread diffusion of 
chronic pathologies, such as type II diabetes. Among the various vascular districts affected by PAD, the 
femoro-popliteal vascular axis is one of the most challenging regions where to perform surgical or 
interventional radiology (IR) procedures due to the constant presence of strong biodynamic forces—
i.e., longitudinal and radial compression, flexion, extension and torsion—, causing stress to the vessel 
walls (1,2). 
 From an interventional radiology perspective, the short-term durability of balloon angioplasty— 
the recommended first-line treatment for PAD—has tipped the balance in favor of femoro-popliteal 
artery stenting, which better preserves vessel patency (3). The sustained benefit of stenting vs 
angioplasty in treating femoro-popliteal obstructions has indeed been reported in multiple studies (1,4–9) 
 Even though many types of stents have been tested in superficial femoral artery (SFA) and 
popliteal artery (PA), the vast majority of these devices have provided an unsatisfactory outcome, 
probably due their unsuitable anatomical and physiological characteristics. For instance, laser cut stents 
have shown several limitations caused by possible rupture, kinking and/or induction of a significant 
inflammatory response on the vessel wall. Nonetheless, the continuous evolution of materials has led to 
the development of biomimetic stents able to reduce the amount of stress on the vessel walls and, at the 
same time, provide greater radial strength and fracture resistance (6,10-12). 
 The Supera peripheral stent (Abbott Vascular, Santa Rosa, CA, USA) is a braided interwoven 
nitinol device specifically designed for treating atherosclerotic lesions of the femoro-popliteal segment. 
 In the present study, we report the results of a multicenter retrospective study on the 
effectiveness of Supera stents in the management of femoral-popliteal atherosclerotic lesions and 
critically analyze our findings in the context of current and past literature. 
 
Design and Methods 
Study design 
This study was designed as a multicenter retrospective study aimed to determine the effectiveness of 
Supera stents in the treatment of complex femoro-popliteal lesions. Primary outcomes included patency 
(i.e., primary, primary assisted and secondary patency), target lesion revascularization (TLR) and 
safety of the device. Moreover, we performed a review of the literature, comparing the results obtained 
in our retrospective study with previously published data. Ethics committee approval was not necessary 
due to the retrospective nature of this study and of the data collected. Data collection does not violate 
patient privacy. The study has been conducted in accordance with the Helsinki Declaration. 
All study participants signed a written informed consent before receiving endovascular treatment. 
Inclusion criteria were patients affected by chronic obstructive arterial disease (COAD) belonging 
category 3, 4 and 5, as per Rutherford classification, treated with endovascular revascularization and 
Supera stent implantation in the femoro-popliteal axis. 
 
Study population 
Between April 2015 and December 2019, 105 endovascular procedures for femoro-popliteal stenting 
with Supera were performed in four Italian hospitals. 
 Demographics, risk factors, ongoing therapies, comorbidities (i.e., chronic heart failure, 
coronary disease, stroke history and diabetes), postoperative outcomes and follow-up data were 
recorded. Clinical symptoms such as intermittent claudication, critical ischemia with rest pain and 
tissue loss were ranked according to Rutherford classification prior to endovascular treatment. 
 In order to analyze and classify the cohort of patients subjected to implantation, the authors 
segmented SFA in three regions: F1 (proximal third), F2 (middle third) and F3 (distal third). Similarly, 
PA was divided in three areas: P1 (from the intercondylar fossa to the proximal edge of patella), P2 
(from the proximal part of the patella to the center of the knee joint space) and P3 (from the center of 
the knee joint space to the origin of the anterior tibial artery). 
 
Supera stent implantation 
All patients underwent initial diagnostic angiography of their lower limbs with standard contrast intra-
arterial digital subtraction angiogram to outline the vascular anatomy and define the lesion 
characteristics. The endovascular stenting was performed by experienced interventional radiologists, 
with more than 10 years of interventional radiology practice, in a dedicated endovascular suite 
alongside a vascular surgeon. Before the beginning of the study, each participating center had to 
implant at least 10 Supera stents. These previous implants were not included in our analysis in order to 
reduce the operator's learning curve bias. 
The interwoven nitinol Supera stent, with his particular chronic outward force and conformability (i.e., 
high resistance to torsion and high radial stiffness), is a unique endovascular device specifically 
designed for districts subject to flexion and torsion, such as the femoral-popliteal district (13). The 
Supera peripheral stent is a woven self-expanding stent constructed from nitinol. Six pairs of closed-
ended interwoven nitinol wires are arranged in a helical pattern designed to be both flexible and 
resistant to fracture and to reduce the risk of re-coiling, especially in vessels affected by atheroma and 
calcification (14). 
The stent comes premounted on an over-the-wire delivery system (6F or 7F) compatible with 0.018 
stent is a woven self-expanding stent constructed from nitinol. The vessel must be pre-dilated before 
the stenting of 1mm more that the stent size. Only standard balloon angioplasty was performed to 
obtain this. 
 When more than one stent was needed, stents were overlapped for at least 10 mm. Digital 
subtraction angiography (DSA) after each procedure recorded the balloon dilatation site and runoff 
vessels to assess diameter improvement and potential complications such as vasospasm, dissection, 
thrombosis or distal embolism (Fig. 1). 
 Before implantation, patients underwent 1-month dual antiplatelet therapy consisting of 
acetylsalicylic acid 100 mg/die and clopidogrel 75 mg/die. After the procedure, acetylsalicylic acid 100 
mg/die was prescribed indefinitely. 
In all case of occlusion, the vessel revascularization of the arterial axis and stent was obtained using a 
intraluminal technique (never subintimal). 
 
Follow-up 
  Any peri-procedural complication (e.g., hematoma, bleeding, pseudoaneurysm and early stent 
occlusion) arising during the 24-h post-implantation period was recorded. Clinical and ultrasound 




The aim of this retrospective study was to conduct a clinical and radiological follow-up in order to 
evaluate stent patency (i.e., primary, primary assisted and secondary patency), TLR and device safety 
following stenting. 
 Between April 2015 and January 2020, we analyzed 112 patients, of whom 7 (6.3%) were 
excluded due to incomplete data. The 99 study participants (69men and 30 women) had a mean age of 
74.5 ± 9.4 years. A total of 105 lower limbs were implanted with a Supera stent. 
 Stratification of the patients according to Rutherford classification indicated that 35 patients 
(35.4%) suffered from severe claudication (walking < 100 m) on admission, 17 patients (17.2%) had 
pain at rest and 47 patients (47.4%) presented with tissue loss. Further details are shown in Table 1. 
 The median follow-up was 39 months (range 6-72). Seventy-nine patients (79.8%) were 
followed up for two years. In the first year post-implantation, 3 patients died (3.0%) due to causes 
unrelated to the endovascular procedure—cardiac failure (2/3) and pneumonia (1/3). Of note, patients 
with less than 6 months of follow-up were excluded from the study. Any case of major bleeding due to 
ongoing antiplatelet therapy was recorded at follow-up as well. 
 Kaplan-Meier curves were calculated using statistical analysis. Primary patency (PP) rates at 
12, 24 and 36 months after the procedure were 83.1%, 74.3% and 69.5% respectively (Fig. 2). Mean PP 
rate was 75.6%. 
 Similar analyses were performed by setting as independent variables the total length of the 
implanted stent (Fig. 3), the stent position in SFA only vs treatment of the PA (Fig. 4) or the size of the 
stent (Fig. 5). 
 We also assessed the relationship between PP rate and total length of the Supera stent placed in 
each treated leg (Fig. 2). To this end, we stratified the patients in three subgroups: < 10 cm (L1), 
between 10 and 18 cm (L2), > 18 cm (L3). In L1 patients, PP rates were 85.7%, 78.5 % and 57.1% 
at12, 24 and 36 months post-implantation, respectively, whereas those in L2 and L3 were 71.4%, 
65.7 %, 51.4% and 87.5%, 72.4%, 68.9%, respectively. 
 Next, we analyzed the relationship between PP rates and treated vessels (SFA alone or together 
with PA) (Fig. 3). On the one hand, patients implanted with Supera stent in SFA alone reported PP rates 
of 85.5%, 71.1 % and 69.5% at 12, 24 and 36 months post-implantation. On the other hand, the patients 
implanted with a Supera stent in both SFA and PA displayed PP rates of 86.4%, 75.2 % and 69.5% at 
12, 24 and 36 months after the procedure, values not significantly different from those observed in the 
SFA alone group. 
 Finally, we analyzed the relationship between PP rate and Supera stent size. For this purpose, 
three cohorts of patients were analyzed, each implanted with Supera stents with different diameters (4, 
5 or 6 mm). The PP rates in patients treated with 4-mm diameter Supera stents were 86.2%, 75.5 % and 
64.5% at 12, 24 and 36 months post-implantation, respectively. In contrast, patients implanted with 
larger diameter Supera stents showed an overall improved PP, with rates of  86.2%, 83.8 % and 72.3% 
(5 mm) and 100%, 83.1 % and 72.3% (6 mm) at the 12, 24 and 36 month time points. Table 2 
summarizes the follow-up results according to the independent variables mentioned above. 




PAD is a growing global problem (5) due to the worldwide increased incidence of type II diabetes and 
other factors, such as smoking, which augment the risk of atheroma development, mostly affecting the 
lower limbs and the femoral-popliteal district, with a worldwide prevalence between 3% to 12% (15). 
Severe ischemia of the lower limbs tends to affect more women than men (about 3: 1), with an 
increasing incidence among individuals older than 40 years of age (16,17). 
 The treatment of this pathology involves numerous surgical and/or radiological interventional 
options that are all the more challenging when carried out in the femoro-popliteal district due to its 
peculiar characteristics. Indeed, the vessels in this anatomically complex district are constantly exposed 
to strong biodynamic forces during daily activities, which makes the vessel wall more prone to 
elongation, kinking and rotation (18).   
 Even though percutaneous angioplasty is the therapeutic gold standard for the treatment of 
patients with moderate stenosis in the femoro-popliteal district, stenting is only recommended in cases 
of severe stenosis and/or dissection (iatrogenic or not) (19). However, this approach does not always 
have a positive outcome due to the massive presence of the aforementioned mechanical forces. For 
example, during knee flexion, stented vessels tend to get stiff and kinked, which may lead to stent 
thrombosis and restenosis (20), especially when the stent is positioned in the intra-articular PA. 
 Indeed, calcific lesions very frequently result in restenosis, patency loss or amputation (21). In 
cadaver models, the Supera stent was shown to be the only type of stent that would not be crushed or 
pinched during hip/knee flexion deformation (22), ensuring optimal luminal flow. This aspect is 
particularly important given that reduced stent kinking may increase stent durability over a 3-year 
period (23). 
 Here, we retrospectively report the experience of four Italian centers with Supera stenting of the 
femoro-popliteal district. In particular, we enrolled primary stenting-treated patients with symptomatic 
atheromasclerotic lesions in SFA and PA and evaluated the outcomes at 3-year follow-up. 
 In terms of population characteristics, our results are in good agreement with those reported by 
San Norberto et al., 2019 (12). Specifically, the mean age and the prevalence of TASC-II D and critical 
limb ischemia recorded in our study are quite similar to those reported by San Norberto et al. (74.5 vs 
74.4 years; 41.9% vs 44%; and 64.4 vs 64%, respectively). In contrast, the lesions treated in this study 
were on average much longer (150.4 vs 114.3 cm) and more often localized in PA (46.5% vs 28%) 
compared to those described by San Norberto et al. 
 We evaluated the follow-up data performed in the centers enrolled three years after the 
procedure. Although multiple stents were positioned with their extremities at the P2 portion of PA, the 
PP rates observed in our study were 83.1%, 74.3% and 69.5% at 12, 24 and 36 months, respectively, 
compared to 89.6%, 72.3% and 70.2% reported by San Norberto et al. at the same time points (12). The 
mean PP rate was 75.6%, in good agreement with previous 3-year follow-up studies, reporting values 
ranging from 74.9 to 77.4% (3,12). 
 Importantly, while the PP rates of Supera stents that we observed at 1 year are very similar to 
those reported by Sibé et al. (24) using Bail-out nitinol stents (83.1% vs 81.5%, respectively), the 2-year 
Supera stent PP rates are substantially higher than those of Bail-out nitinol stents (74.3 vs 67.2%, 
respectively). 
 The assisted PP rate at 1 year observed in our study (89.4%) is in line with those reported by 
other studies, with values ranging from 80.5% to 94% (3,9,10,12,23,25–31). 
 Considering that the use of the Supera stent requires a greater learning curves then traditional 
bare stents, the inter-operator variability could represent a study bias.(22) 
 Chan et al. have recently published one of the longest follow-up studies in patients treated with 
Supera stents. From their results, it emerges that 4-mm stents tend to have a PP < 5 mm for the first 46 
months (P = 0.131). Our results at 32-month follow-up up indicate a lower PP in 4-mm stents 
compared to that observed in 5- or 6-mm stents (P = 0.028). This result may be affected by a bias due 
to the positioning of the stents. In fact, the 4-mm Supera were more frequently placed in PA, where the 
PP rate is generally lower than that of SFA-positioned stents. Further studies stratifying the results 
according to the position of the stent along the arterial axis may resolve this discrepancy. 
 The TLR of Supera stent has been evaluated in numerous studies. Currently, the value of 
freedom from TLR at 3 years is between 70% and 94% (cited articles in the bulleted list). Our 
multicenter study reported a freedom from TLR at 12, 24 and 36 months of 92.7%, 91.5% and 89.5%, 
respectively, which can be superimposed on the current scientific literature (9,28,29,32). 
 Recently, Gouëffic et al. have compared polymer-free self-expanding paclitaxel-eluting stents 
with bare-metal stents in femoropopliteal lesion treatment. The authors reported a PP for the polymer-
free stent of 85.1% at 1-year follow-up and 78.8% at 2-year follow-up, while the freedom from TLR 
was 93.6% and 87.2% at the same follow-ups. Bare-metal stents were found not to be superior to 
paclitaxel-eluting stents at both 1- and 2-year follow-ups (PP: 84.8% and 74.6%; freedom from TLR: 
93.3% and 87.6%, respectively). Similarly, our results seem to indicate that Supera stents are not 
superior to polymer-free self-expanding paclitaxel-eluting stents with bare-metal stents in 
femoropopliteal lesion treatment. Future studies on more homogeneous patient cohorts are clearly 
needed to further test this hypothesis. 
 Lastly, we report a mortality rate at 12 months of 3% (3 patients out of 99 enrolled). This is 
similar to what reported by Armstrong et al. in a comparative study of Supera stents vs bare nitinol 




This study highlights the excellent safety and effectiveness profile and high durability of Supera stents 
for the treatment of PAD patients with femoro-popliteal artery disease. Despite treating long and severe 
stenosis, we managed to obtained good values of freedom from TLR at 3 years post-implantation. 
Thus, the Supera stent should be considered a valid option for primary stenting in this anatomically 
complex vascular district. 
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Table 1: Study Population 
Variable No. of patients 
(n=99) 
% 
Risk factors   
Smoking 95 96.0 
Hypertension 93 93.9 
Hyperlipidemia 83 83.8 
Diabetes 85 85.9 
 No. of legs (n=105) % 
Clinical category   
1 0 0 
2 0 0 
3 36 34.3 
4 19 18.1 
5 49 46.7 
6 0 0 
Diseased segment   
SFA   
Proximal 12 11.4 
Middle 55 52.4 
Distal 56 53.3 
PA   
ATK 13 12.4 
BTK 15 14.3 
ATK & BTK 18 17.1 
TASC   
A 9 8.6 
B 36 34.3 
C 16 15.2 
D 44 41.9 
Occluded lesions 44 41.9 
No. of run-off vessels   
0 1 0.96 
1 39 37.1 
2 44 41.9 
3 21 20 
FA, superficial femoral artery; PA, popliteal artery; ATK, above the knee; BTK, below the knee; TASC, 
Trans-Atlantic Inter-Society Consensus. 
 
 












Primary patency  83.1 74.3 69.5 
Primary patency assisted 89.94 76.8 73.4 
Freedom from TLR  92.7 91.5 89.5 
Total length of the Supera stent Group L1 85.7 78.5 57.1 
 Group L2 71.4 65.7 51.4 
 Group L3 87.5 72.4 68.9 
Stent position SFA 85.5 71.1 69.5 
 PA or 
SFA+PA 
86.4 75.2 69.5 
Stent size 4    
 5    
 6    
TLR, target lesion revascularization; SFA, superficial femoral artery; PA, popliteal artery 
 
Figure 1. DSA before e post Supera stent placement. The stent allowed vessel caliber restoration 
 
Figure 2.  Primary patency rate of Supera stent during follow-up. 36 months after procedure, the 




Figure 3. Relationship between primary patency rate and total length of the Supera stent implanted. 
Kaplan-Meyer analysis did not reveal any statistical difference between the three groups (L1: < 10 cm, 
L2: between 10 and 18 cm, L3: >18 cm). 
 
 
Figure 4. Position of Supera stent (SFA only or combination with popliteal artery) as a function of its 
primary patency. Treatments of the popliteal alone were not stratified due to their small number 
(4/105). 
 
Figure 5. Relationship between stent patency and its size. Small stents reported a lower patency values 
at 36 months 
 
 
 
